Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30092682)

  • 1. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
    El Dika I; Ilson DH
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
    Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
    Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
    Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
    Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of autophagy in HER2-targeted therapy.
    Janser FA; Tschan MP; Langer R
    Swiss Med Wkly; 2019 Oct; 149():w20138. PubMed ID: 31656036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enrichment of
    Mitra D; Clark JW; Shih HA; Oh KS; Brastianos PK; Wo JY; Strickland MR; Curry WT; Parikh AR; Corcoran RB; Ryan DP; Iafrate AJ; Borger DR; Lennerz JK; Hong TS
    Oncologist; 2019 Feb; 24(2):193-201. PubMed ID: 30373904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.
    Dokmanovic M; King KE; Mohan N; Endo Y; Wu WJ
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):755-766. PubMed ID: 28571477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
    Awada G; Gombos A; Aftimos P; Awada A
    Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab in gastrointestinal cancer.
    Oh DY; Bang YJ
    Expert Opin Biol Ther; 2016; 16(2):243-53. PubMed ID: 26619359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.
    Fusco N; Bosari S
    World J Gastroenterol; 2016 Sep; 22(35):7926-37. PubMed ID: 27672288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in novel targeted therapies for HER2-positive breast cancer.
    Murphy CG; Morris PG
    Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
    Takegawa N; Yonesaka K
    Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers.
    Kim YS; Lee HJ; Park JM; Han YM; Kangwan N; Oh JY; Lee DY; Hahm KB
    Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):1059-1070. PubMed ID: 28707966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.